Tandem Enterprise Value over EBIT from 2010 to 2024

TNDM Stock  USD 31.73  1.30  4.27%   
Check Tandem Diabetes financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tandem main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.4 M, Interest Expense of 5.8 M or Selling General Administrative of 370.1 M, as well as many exotic indicators such as Price To Sales Ratio of 2.44, Dividend Yield of 0.0 or PTB Ratio of 4.71. Tandem financial statements analysis is a perfect complement when working with Tandem Diabetes Valuation or Volatility modules.
  
This module can also supplement Tandem Diabetes' financial leverage analysis and stock options assessment as well as various Tandem Diabetes Technical models . Check out the analysis of Tandem Diabetes Correlation against competitors.

About Tandem Diabetes Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Tandem Diabetes income statement, its balance sheet, and the statement of cash flows. Tandem Diabetes investors use historical funamental indicators, such as Tandem Diabetes's Enterprise Value over EBIT, to determine how well the company is positioned to perform in the future. Although Tandem Diabetes investors may use each financial statement separately, they are all related. The changes in Tandem Diabetes's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Tandem Diabetes's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Tandem Diabetes Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Tandem Diabetes. Please read more on our technical analysis and fundamental analysis pages.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. Tandem Diabetes operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2000 people.

Tandem Diabetes Investors Sentiment

The influence of Tandem Diabetes' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Tandem. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Tandem Diabetes' public news can be used to forecast risks associated with an investment in Tandem. The trend in average sentiment can be used to explain how an investor holding Tandem can time the market purely based on public headlines and social activities around Tandem Diabetes Care. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Tandem Diabetes' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Tandem Diabetes' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Tandem Diabetes' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Tandem Diabetes.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tandem Diabetes in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tandem Diabetes' short interest history, or implied volatility extrapolated from Tandem Diabetes options trading.

Currently Active Assets on Macroaxis

When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
Check out the analysis of Tandem Diabetes Correlation against competitors.
Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Tandem Stock analysis

When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Money Managers
Screen money managers from public funds and ETFs managed around the world
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.37)
Earnings Share
(3.43)
Revenue Per Share
11.509
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.1)
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.